You are here: Industry Insights > Market News > Hikma intends to acquire assets in Egypt, Tunisia

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Hikma intends to acquire assets in Egypt, Tunisia

expresspharmaJanuary 27, 2021

Tag: Hikma , GSK , Tunisia

Favorites

Hikma Pharmaceuticals said it was planning to buy GSK’s stake in some assets including the drugmaker’s pharma, consumer commercialisation and manufacturing business in Egypt and its drugs business in Tunisia.

The company, which supplies many generic drugs including anaesthetics, pain medications, sedatives, neuromuscular blocking agents and anti-infectives, said further talks with GSK will depend on the results of its due-diligence process.

Previous:Sanofi to produce 100 million Pfizer/BioNTech vaccine doses: CEO

Next:Misinformation, future of work among key pharma trends in 2021: GlobalData

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

The life science group Sartorius is collaborating with biopharmaceutical company Sanofi to develop an end-to-end platform for integrated and continuous downstream bioprocessing.

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

Hikma intends to acquire assets in Egypt, Tunisia | Pharmasources.com

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

Biotech NewswireMay 09, 2024

MetP Pharma AG, leveraging the proprietary nose-to-brain drug delivery technology BrainDos™ in internal and external product development and manufacturing programs.

Hikma intends to acquire assets in Egypt, Tunisia

Related News

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

You may like